Diamond Therapeutics has received approval from Health Canada to carry out a Phase 2 low-dose psilocybin trial for the treatment of generalised anxiety disorder (GAD) on...
Small Pharma has reported positive top-line results from its Phase 2a Trial of SPL026 in Major Depressive Disorder (MDD).
Algernon Pharmaceuticals has announced that its subsidiary, Algernon NeuroScience (AGN Neuro), has dosed the first subject in its Phase 1 clinical study of an intravenous formulation...
Psychedelics are being touted as a potential breakthrough in the area of mental health treatment.
Biopharmaceutical company Cybin has selected generalised anxiety disorder (GAD), with or without major depressive disorder (MDD), as the target indication for its proprietary deuterated DMT molecule,...
Silo Pharma is advancing its clinical study exploring psilocybin’s effect on inflammation, targeting conditions such as Parkinson’s disease, bipolar disorder and chronic pain.
Reunion Neuroscience has completed the interim data analysis for its Phase 1 clinical trial with lead asset RE104, a unique 4-OH-DiPT prodrug.
The first patient has been dosed in Small Pharma’s Phase I study that is comparing the profiles of the company’s proprietary formulation of DMT.
A global ayahuasca survey has found 70% experience physical and 55% mental health adverse effects, but only 2.3% of participants reporting physical adverse events required medical...
Tryp has announced interim data for the first five patients dosed in its Phase 2 trial, stating the data supports the potential effectiveness of psilocybin-assisted psychotherapy...